• Dr. Gunda Georg

    A new drug for pancreatic cancer takes the stage for clinical trials

    What does it take to get to that moment in a clinic when a doctor gives a patient a compound never before used in modern medicine? The story of Minnelide, an investigational drug for pancreatic cancer patients now in a Phase IA clinical trial at the University of Minnesota, illustrates just how complex and exhilarating that journey can be.

    Read more

  • Gunda George

    Gamechanger: Gunda Georg

    Gunda Georg is an esteemed researcher and professor who has made a tremendous impact in the field of synthetic medicinal chemistry.

    Read more

  • Abstract image

    Gunda Georg Inducted into the Academy for Excellence in Health Research

    The Academy for Excellence in Health Research is the highest recognition of excellence in research by Academic Health Center faculty

    Read more

  • Gunda Georg, and Vadim JGurvich

    Welcome to the Institute for Therapeutics Discovery & Development

    ITDD creates opportunities for drug discovery and early pre-clinical drug development through collaborations between various schools, colleges and research centers, as well as industrial throughout Minnesota and nationwide.

    Learn more about our scientific services

  • pills

    Hormone-Free Birth Control Research Advances

    Researchers will investigate pharmaceutical alternatives to existing hormone-based birth control under a new $8.3M NIH contract.

 The Journal of Medicinal Chemistry

The Journal of Medicinal Chemistry publishes studies that contribute to an understanding of the relationship between molecular structure and biological activity or mode of action.

See journal


Jon Hawkinson Received NIH Shared Instrumentation Award

Jon Hawkinson, director of the ITDD High-throughput Screening Laboratory, received a $343,887 NIH shared instrumentation award for the plasmon resonance (SPR) instrument, which will allow


Dr. Vadim Gurvich receives R01 funding

Vadim Gurvich, ITDD Associate Director, received $68,400 for his part of an R01 project, "Toward a Mechanism-Based Approach to Treating Atrial Fibrillation."

Peter Dosa Featured in College of Pharmacy annual report

The College of Pharmacy's 2014 annual report highlights associate program director Peter Dosa's research in "


Gunda GeorgGunda I. Georg, PhD

Director, Institute for Therapeutics Discovery and Development
Professor and Department Head, Department of Medicinal Chemistry; Robert Vince Endowed Chair; McKnight Presidential Chair

Dr. Georg’s expertise includes synthetic medicinal agents, natural products chemistry, and the development of new synthetic methods. She is the co-inventor of Lusedra® and several other drug candidates, as well as the co-founder of ProQuest Pharmaceuticals, Inc. (now a part of Eisai Pharmaceuticals). The ITDD core directors have extensive academic and industrial drug discovery and development expertise. The group uses advanced research and development techniques, including high through-put screening, structure-based drug design, computer modeling, chem- and bioinformatics methods, and animal models to translate basic biomedical discoveries towards new approaches for prevention, treatment, and cures

Vadim GurvichVadim J. Gurvich, PhD, MBA

Associate Director, Institute for Therapeutics Discovery and Development
Director, Chemical Process Development Core

Michael WaltersMichael A. Walters, PhD

Director, Lead and Probe Discovery Core
Institute for Therapeutics Discovery and Development